Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. S...
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2478
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT04484818
- Locations
- 🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Conditions
- Interventions
- Procedure: Computed TomographyRadiation: 3-Dimensional Conformal Radiation TherapyDrug: ApalutamideDrug: DegarelixRadiation: External Beam Radiation TherapyOther: Fluciclovine F18Drug: Goserelin AcetateDrug: Leuprolide AcetateProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Intensity-Modulated Proton TherapyOther: Quality-of-Life AssessmentRadiation: Intensity-Modulated Radiation TherapyOther: Questionnaire AdministrationDrug: RelugolixDrug: TriptorelinRadiation: Stereotactic Body Radiation TherapyRadiation: Volume Modulated Arc Therapy
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 804
- Registration Number
- NCT04423211
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Wonju Severance Christian Hospital
- Target Recruit Count
- 164
- Registration Number
- NCT04248621
- Locations
- 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of
Long-term Better Than Short-term ADT With Salvage RT
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 394
- Registration Number
- NCT04242017
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇧🇪AZ Maria Middelares, Gent, Belgium
Generation of Biological Samples Positive to Triptorelin for Anti-doping Control
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 2
- Registration Number
- NCT04189900
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 1892
- Registration Number
- NCT03809221
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: AbirateroneDrug: BicalutamideDrug: DegarelixDrug: FlutamideDrug: DocetaxelDrug: Goserelin AcetateDrug: Histrelin AcetateDrug: Leuprolide AcetateDrug: NilutamideProcedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: PrednisoneProcedure: Radical ProstatectomyDrug: Triptorelin
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Single Dose Recombinant Human Follicle Stimulating Hormone Fc Husion Protein (KN015) in Healthy Volunteers
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Alphamab Jilin Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03192527
- Locations
- 🇨🇳
The First Hospital of Jilin University, Chuangchun, Jilin, China
The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- American University of Beirut Medical Center
- Target Recruit Count
- 277
- Registration Number
- NCT03169166
- Locations
- 🇱🇧
American University of Beirut Medical Center, Beirut, Lebanon
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.